February 2006

USP Pharmaceutical Waters, Part 1 logo in a gray background | USP Pharmaceutical Waters, Part 1
Biochemicals/Raw Materials
USP Pharmaceutical Waters, Part 1USP Pharmaceutical Waters, Part 1
USP Pharmaceutical Waters, Part 1
Feb 1, 2006
byBPI Contributor
Global Meetingplace logo in a gray background | Global Meetingplace
Business
Global MeetingplaceGlobal Meetingplace
Global Meetingplace
Feb 1, 2006
byBPI Contributor
Enterprise Resource Planning Systems logo in a gray background | Enterprise Resource Planning Systems
Information Technology
Enterprise Resource Planning SystemsEnterprise Resource Planning Systems
Enterprise Resource Planning Systems
Feb 1, 2006
byBPI Contributor
Design and Scale-Up of Bioreactors Using Computer Simulations logo in a gray background | Design and Scale-Up of Bioreactors Using Computer Simulations
Information Technology
Design and Scale-Up of Bioreactors Using Computer SimulationsDesign and Scale-Up of Bioreactors Using Computer Simulations
Design and Scale-Up of Bioreactors Using Computer Simulations
Feb 1, 2006
byBPI Contributor
Capacity Bottleneck Squeezed By Downstream Processes logo in a gray background | Capacity Bottleneck Squeezed By Downstream Processes
Facility Design/Engineering
Capacity Bottleneck Squeezed By Downstream ProcessesCapacity Bottleneck Squeezed By Downstream Processes
Capacity Bottleneck Squeezed By Downstream Processes
Feb 1, 2006
byBPI Contributor
Controlling and Monitoring Critical Workspace Environments logo in a gray background | Controlling and Monitoring Critical Workspace Environments
Facility Design/Engineering
Controlling and Monitoring Critical Workspace EnvironmentsControlling and Monitoring Critical Workspace Environments
Controlling and Monitoring Critical Workspace Environments
Feb 1, 2006
byBPI Contributor
Products, Services, and Literature logo in a gray background | Products, Services, and Literature
Business
Products, Services, and Literature February 2006Products, Services, and Literature February 2006
Products, Services, and Literature
Feb 1, 2006
byBPI Contributor
The Critical Role of Bioprocessing Contracts logo in a gray background | The Critical Role of Bioprocessing Contracts
Business
The Critical Role of Bioprocessing ContractsThe Critical Role of Bioprocessing Contracts
The Critical Role of Bioprocessing Contracts
Feb 1, 2006
byBPI Contributor
Meetingplace logo in a gray background | Meetingplace
Business
MeetingplaceMeetingplace
Meetingplace
Feb 1, 2006
byBPI Contributor
Parenteral Packaging Concerns for Biotech Drugs logo in a gray background | Parenteral Packaging Concerns for Biotech Drugs
Fill/Finish
Parenteral Packaging Concerns for Biotech DrugsParenteral Packaging Concerns for Biotech Drugs
Parenteral Packaging Concerns for Biotech Drugs
Feb 1, 2006
byBPI Contributor
Accelerating Biopharmaceutical Product Development, Part 1 logo in a gray background | Accelerating Biopharmaceutical Product Development, Part 1
Process Development
Accelerating Biopharmaceutical Product Development, Part 1Accelerating Biopharmaceutical Product Development, Part 1
Accelerating Biopharmaceutical Product Development, Part 1
Feb 1, 2006
byBPI Contributor
A 96-Well Plate Assay for Relative Monoclonal Antibody Titers logo in a gray background | A 96-Well Plate Assay for Relative Monoclonal Antibody Titers
Assays
A 96-Well Plate Assay for Relative Monoclonal Antibody TitersA 96-Well Plate Assay for Relative Monoclonal Antibody Titers
A 96-Well Plate Assay for Relative Monoclonal Antibody Titers
Feb 1, 2006
byBPI Contributor
Virus in Vogue logo in a gray background | Virus in Vogue
MAb
Virus in VogueVirus in Vogue
Virus in Vogue
Feb 1, 2006
byBPI Contributor
Managing a Biopharmaceutical Supply Chain logo in a gray background | Managing a Biopharmaceutical Supply Chain
Supply Chain
Managing a Biopharmaceutical Supply ChainManaging a Biopharmaceutical Supply Chain
Managing a Biopharmaceutical Supply Chain
Feb 1, 2006
byBPI Contributor
Large-Scale Beta-Propiolactone Inactivation of HIV for Vaccines logo in a gray background | Large-Scale Beta-Propiolactone Inactivation of HIV for Vaccines
MAb
Large-Scale Beta-Propiolactone Inactivation of HIV for VaccinesLarge-Scale Beta-Propiolactone Inactivation of HIV for Vaccines
Large-Scale Beta-Propiolactone Inactivation of HIV for Vaccines
Feb 1, 2006
byBPI Contributor
High-Concentration UF/DF of a Monoclonal Antibody logo in a gray background | High-Concentration UF/DF of a Monoclonal Antibody
Filtration
High-Concentration UF/DF of a Monoclonal AntibodyHigh-Concentration UF/DF of a Monoclonal Antibody
High-Concentration UF/DF of a Monoclonal Antibody
Feb 1, 2006
byBPI Contributor
An Approach to Optimizing Large-Scale Cell Harvest logo in a gray background | An Approach to Optimizing Large-Scale Cell Harvest
Separation/Purification
An Approach to Optimizing Large-Scale Cell HarvestAn Approach to Optimizing Large-Scale Cell Harvest
An Approach to Optimizing Large-Scale Cell Harvest
Feb 1, 2006
byBPI Contributor
A Ceramic Hydroxyapatite-Based Purification Platform logo in a gray background | A Ceramic Hydroxyapatite-Based Purification Platform
Separation/Purification
A Ceramic Hydroxyapatite-Based Purification PlatformA Ceramic Hydroxyapatite-Based Purification Platform
A Ceramic Hydroxyapatite-Based Purification Platform
Feb 1, 2006
byBPI Contributor

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges
Register Now: Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges
Ask the Expert webcasts
ATE Webcasts
Register Now: Linking mAb Product Quality Profile Changes to Your Bioprocess: Case Study of Dynamic Glucose Level Control in CHO Process Improves Product Quality
Register Now: Linking mAb Product Quality Profile Changes to Your Bioprocess: Case Study of Dynamic Glucose Level Control in CHO Process Improves Product Quality
Ask the Expert webcasts
ATE Webcasts
Register Now: Navigating Biopharma Commercialization: The Interplay of Regulatory Affairs, Process Development, and Manufacturing to Ensure Drug Quality
Register Now: Navigating Biopharma Commercialization: The Interplay of Regulatory Affairs, Process Development, and Manufacturing to Ensure Drug Quality
Insider News
See all
Dec 2 - Dec 5, 2024
The European Cell and Gene Therapy Congress for Groundbreaking Manufacturing, Commercialisation & Analytical Strategies: World renowned leaders share the latest process development, analytical and market access strategies to improve manufacturing scalability, quality and cost to propel your CGT programmes to commercial success
Learn More

Innovative Technology

Emerson white paper
Sponsored Content
Sustainability in Life Sciences: Actionable Solutions for Improving Energy Efficiency
Sustainability in Life Sciences: Actionable Solutions for Improving Energy Efficiency

Nov 12, 2024

WuXi Bio white paper
Sponsored Content
Empowering Modern Drug Product Development: Breakthroughs in High-Concentration Formulations and Drug-Device Combination Products
Empowering Modern Drug Product Development: Breakthroughs in High-Concentration Formulations and Drug-Device Combination Products

Nov 8, 2024

Bora white paper
Sponsored Content
Redefining Scalability: Strategies for Enhancing Early Drug Development to Future-Proof Later Stages
Redefining Scalability: Strategies for Enhancing Early Drug Development to Future-Proof Later Stages

Nov 8, 2024